Valuation : Delcath Systems, Inc.

Market Cap 554M 477M 449M 409M 766M 52.76B 769M 5.32B 2.06B 26.88B 2.08B 2.04B 85.16B P/E 2026 *
-107x
P/E 2027 * -200x
Enterprise Value 554M 477M 449M 409M 766M 52.76B 769M 5.32B 2.06B 26.88B 2.08B 2.04B 85.16B EV / Sales 2026 *
5.22x
EV / Sales 2027 * 4.2x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%-3.26%-0.49%-27.49% 18.45B
-1.64%-4.13%-5.72%+5.67% 16.98B
+0.75%-3.22%-54.61%-49.01% 6.6B
-1.05%-5.02% - - 4.27B
+1.42%-0.36%+35.42%+72.00% 2.07B
-2.11%-3.97%-10.16%-8.09% 1.88B
-2.41%-0.78%-50.76%-56.58% 1.16B
-0.62%-3.62%+37.76%+232.22% 558M
-0.49%+0.99% - - 298M
Average -0.72%-1.01%-6.94%+24.10% 5.81B
Weighted average by Cap. -0.75%-1.69%-9.44%-11.25%

Financials

2026 *2027 *
Net sales 106M 91.39M 86.06M 78.41M 147M 10.11B 147M 1.02B 394M 5.15B 399M 390M 16.31B 132M 114M 107M 97.44M 182M 12.56B 183M 1.27B 490M 6.4B 496M 485M 20.27B
Net income -5.72M -4.92M -4.64M -4.22M -7.9M -544M -7.93M -54.94M -21.23M -277M -21.48M -21.02M -879M -3.39M -2.92M -2.75M -2.5M -4.68M -322M -4.7M -32.53M -12.57M -164M -12.72M -12.45M -520M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!